IMA101

News alerts, weekly reports and conference planners

Company:

Immatics

Drug class:

TCR modulator

Related drugs:

‹

›

5ms

Autologous engineered T cell receptor therapy in advanced cancer. (PubMed, Hum Vaccin Immunother)

Of 214 screened patients, 14 were treated (6, IMA101; 8, IMA101 and atezolizumab). Target-specific T cells expanded to constitute up to 78.7% of CD8+ cells. In conclusion, IMA101 was feasible and well tolerated, leveraging the potential of multi-targeted ACT that warrants further investigation.

5 months ago

Review • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases

CD8 (cluster of differentiation 8) • CTAG1B (Cancer/testis antigen 1B) • IL2 (Interleukin 2) • MAGEA4 (Melanoma antigen family A, 4) • PRAME (Preferentially Expressed Antigen In Melanoma) • COL6A3 (Collagen Type VI Alpha 3 Chain) • MMP1 (Matrix metallopeptidase 1) • MAGEA1 (MAGE Family Member A1)

PRAME expression

Tecentriq (atezolizumab) • IMA101

10ms

Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer. (PubMed, Cancer Immunol Res)

Patients received lymphodepletion (fludarabine, cyclophosphamide), followed by T-cell infusion and low-dose IL2 (Cohort 1). Patients in Cohort 2 received atezolizumab for up to 1 year (NCT02876510)...This study demonstrates the feasibility and tolerability of an actively personalized ACT directed to multiple defined pHLA cancer targets. Results warrant further evaluation of multi-target ACT approaches using potent high-avidity TCRs.

10 months ago

P1 data • Journal • Metastases

CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A)

HLA-A*02:01 • HLA-A*02

Tecentriq (atezolizumab) • cyclophosphamide • fludarabine IV • IMA101